my account
Login
  Loading... Please wait...

News

Small molecules for SARS-CoV-2 research

Posted

The novel coronavirus SARS-CoV-2 is rapidly spreading around the globe causing tens of thousands of cases of COVID-19.  As of yet, there are no agents clinically validated to help stop the spread of this virus.   Gordon et al. recently identified 332 SARS-CoV-2-human protein-protein interactions and 67 druggable human proteins as potential targets for developing therapeutics (note that this paper has not yet been subject to peer review).  Focus Biomolecules has created a chart of these targets and validated small molecule modulators.  These are all in stock and ready for immediate shipment.

MC# Name Primary activity COVID-19 rationale
10-1009 Na Valproate 2 HDAC inhibitor HDAC2 interacts with SARS-CoV-2 Nsp5
10-1062 Cycloheximide-N-ethylethanoate2 FKBP12 inhibitor mTORC1 pathway members interact with SARS-CoV-2 N and Orf8 proteins
10-1089 Nafamostat mesylate2 Serine protease inhibitor Targets viral cell entry via inhibition of ACE2
10-1103 FK-5062 FKBP inhibitor mTORC1 pathway members interact with SARS-CoV-2 N and Orf8 proteins
10-1104 Rapamycin2 mTOR inhibitor mTORC1 pathway members interact with SARS-CoV-2 N and Orf8 proteins
10-1105 PKC-412 (Midostaurin)2 Protein kinase inhibitor (pan specific) Inhibits MARK2/3, which interact with SARS-CoV-2 Orf9b
10-1111 Verapamil2 L-type Ca2+ channel blocker Targets Multidrug resistance-associated protein 1 (MRP1), which interacts with SARS-CoV-2 Orf9c
10-1281 Ribavirin2 Antiviral agent Inhibits IMPDH2, which interacts with SARS-CoV-2 Nsp14
10-1311 MLN4924 (Pevonedistat)2 Nedd8 activating enzyme inhibitor Targets Cullin2, which interacts with SARS-CoV-2 Orf10
10-1361 JQ12 Bromodomain inhibitor SARS-CoV-2 transmembrane protein E binds to the bromodomain-containing proteins BRD2 and BRD4
10-1379 Hydroxychloroquine sulfate
Autophagy inhibitor In clinical trials (alongside chloroquine) for SARS-CoV-2 infection
10-1458 GBR-12909
Dopamine reuptake inhibitor Sigma receptor agonist (SARS-CoV-2 Nsp6 protein interacts with the Sigma receptor)
10-1487 RVX-2082 BET bromodomain inhibitor SARS-CoV-2 transmembrane protein E binds to the bromodomain-containing proteins BRD2 and BRD4
10-1569 Dabrafenib (GSK2118436)2 B-Raf mutant inhibitor Inibits NEK9, which interacts with SARS-CoV-2 Nsp9
10-2025 Entacapone2 COMT inhibitor COMT interacts with SARS-CoV-2 Nsp7
10-2057 Apicidin2 HDAC inhibitor HDAC2 interacts with SARS-CoV-2 Nsp5
10-2059 Ascomycin
FKBP ligand mTORC1 pathway members interact with SARS-CoV-2 N and Orf8 proteins
10-2060 Bafilomycin A12 Vacuolar H+ ATPase inhibitor V1-ATPase subunits interact with SARS-CoV-2 Nsp6 and M
10-2087 Mycophenolic acid2 Immunosuppressant Inhibits IMPDH2, which interacts with SARS-CoV-2 Nsp14
10-2144 H892 PKA inhibitor PKA interacts with SARS-CoV-2 Nsp13
10-2196 Camostat mesylate1,2 Serine protease inhibitor Targets viral cell entry via inhibition of ACE2
10-2253 Captopril2 ACE inhibitor Targets viral cell entry via inhibition of ACE2
10-2429 Daunorubicin2 DNA damaging agent Targets Multidrug resistance-associated protein 1 (MRP1), which interacts with SARS-CoV-2 Orf9c
10-2469 Metformin2 Antidiabetic agent Indirect modulator of mTORC1 complex; mTORC1 pathway members interact with SARS-CoV-2 N and Orf8 proteins
10-2473 Chloroquine phosphate2 Autophagy inhibitor Sigma 1 receptor binder (SARS-CoV-2 Nsp6 protein interacts with the Sigma receptor)
10-2474 Niclosamide3 STAT3 signaling inhibitor Regulates mTORC1 pathway, whose members interact with SARS-CoV-2 N and Orf8 proteins
10-2631 Triptolide
NFkB transcriptional activation inhibitor Also directly inhibits dCTP pyrophosphatase 1 (DCTPP1), which interacts with SARS-CoV-2 Orf9b
10-3362 INK-128 (Sapanisertib)2 mTOR inhibitor mTORC1 pathway members interact with SARS-CoV-2 N and Orf8 proteins
10-3613 Santacruzamate A
Ultrapotent HDAC2 inhibitor HDAC2 interacts with SARS-CoV-2 Nsp5
10-3900 Tigecycline2 Antibiotic Like Azithromycin, has off-target effect on mitochondrial ribosomes, components of which interact with the SARS-CoV-2 Nsp8 protein
10-3970 N4-Hydroxycytidine4 Novel antiviral Has antiviral activity against SARS-CoV-2
10-4003 Pridopidine
Sigma-1 Ligand Sigma 1 receptor agonist (SARS-CoV-2 Nsp6 protein interacts with the Sigma receptor)
10-4030 Bromosporine
Pan-bromodomain inhibitor SARS-CoV-2 transmembrane protein E binds to the bromodomain-containing proteins BRD2 and BRD4
10-4121 BI 2536
Dual Plk/BRD4 inhibitor SARS-CoV-2 transmembrane protein E binds to the bromodomain-containing proteins BRD2 and BRD4
10-4122 I-BET762
BET Bromodomain inhibitor SARS-CoV-2 transmembrane protein E binds to the bromodomain-containing proteins BRD2 and BRD4
10-4200 NE-100
Selective sigma-1 antagonist Sigma 1 receptor antagonist (SARS-CoV-2 Nsp6 protein interacts with the Sigma receptor)
10-4201 S1RA (E-52862)2 Selective sigma-1 antagonist Sigma 1 receptor antagonist (SARS-CoV-2 Nsp6 protein interacts with the Sigma receptor)
10-4203 PRE084
Selective sigma-1 agonist Sigma 1 receptor agonist (SARS-CoV-2 Nsp6 protein interacts with the Sigma receptor)
10-4204 DTG
High affinity sigma receptor agonist Sigma receptor agonist (SARS-CoV-2 Nsp6 protein interacts with the Sigma receptor)
10-4210 BD1047 dihydrobromide
Selective sigma-1 antagonist Sigma 1 receptor antagonist (SARS-CoV-2 Nsp6 protein interacts with the Sigma receptor)
10-4219 SA4503
Potent and selective sigma 1 agonist Sigma 1 receptor agonist (SARS-CoV-2 Nsp6 protein interacts with the Sigma receptor)
10-4511 Ruxolitinib2 JAK inhibitor Inhibits MARK2/3, which interact with SARS-CoV-2 Orf9b
10-4544 7-Cl-O-Nec1
RIPK1 inhibitor RIP kinase 1 interacts with SARS-CoV-2 Nsp12
10-4611 RIPA-56
RIP1 inhibitor (more potent than 7-Cl-Nec1) RIP kinase 1 interacts with SARS-CoV-2 Nsp12
10-4818 Volasertib
Polo-like Kinase 1 inhibitor Also inhibits BRD4; SARS-CoV-2 transmembrane protein E binds to the bromodomain-containing proteins BRD2 and BRD4

A potential new role for RIP1 kinase

Researchers have discovered that inhibition of RIP1 kinase blocks the progression of multiple sclerosis in an immune-induced demyelination mouse model (EAE) but not a chemically-induced one (CPZ). RIPA-56 (Focus Biomolecules Cat# 10-4611) blocked disease progression at a step of monocyte elevation downstream of T-cell activation and myelin-specific antibody generation but upstream of blood-brain barrier breakdown. This [...]

Read More »


SHP099 targets ALK inhibitor resistant cancer

Multiple cellular pathways can lead to acquired resistance to ALK inhibitors.  A common pathway is activation of alternate kinase pathways, including EGFR, KIT, SRC, and IGF1R to maintain activation of downstream ERK and/or PI3K-AKT signaling.  Addition of inhibitors to these pathways is a viable response, but not optimal due to the presence of multiple alternatives. Dardaei [...]

Read More »


REV-ERB agonists and Cancer

Researchers at the Salk Institute, the University of California, and the University of Texas have identified a potential new class of cancer therapeutics. REV-ERBs are nuclear hormone receptors that are critical components of the circadian clock, the body's mechanism for establishing daily rhythms in cellular proliferation, metabolism, and other essential processes.  Dysregulation of this system is [...]

Read More »




Focus BiomoleculesPlymouth Meeting, PA USA1-855-FOCUS21

Connect with Focus